Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9231221 | 0.87 | MEN1 (0.47) | GAAOPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL1976788 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2GAARAB9AOPRM1DGAT2 | |
| SCHEMBL1981191 | 0.85 | DGAT2 (0.53) | SMN1; SMN2RAB9AOPRM1DGAT2ALDH1A1 | |
| SCHEMBL9230058 | 0.85 | CYP2D6 (0.57) | SMN1; SMN2GAAOPRM1OPRD1OPRK1 | |
| SCHEMBL1974968 | 0.84 | PLK1 (0.55) | SMN1; SMN2GAANPC1RAB9AALDH1A1 | |
| SCHEMBL11642022 | 0.84 | HSD17B10 (0.44) | SMN1; SMN2HSD17B10CTSLCTSKGAA | |
| SCHEMBL1976483 | 0.81 | EPHX2 (0.47) | CTSLALDH1A1 | |
| SCHEMBL25199371 | 0.81 | HSD17B10 (0.42) | SMN1; SMN2HSD17B10CTSLCTSKGAA | |
| SCHEMBL9231743 | 0.81 | OPRD1 (0.44) | SMN1; SMN2HSD17B10CTSLCTSKGAA | |
| SCHEMBL1992821 | 0.80 | ALOX15 (0.50) | SMN1; SMN2NPC1RAB9ADGAT2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509981-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | LILLY CO ELI (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-2509981-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | LILLY CO ELI (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8299061-B2 | Inhibitors of diacylglycerol acyltransferase | ELI LILLY AND COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299061-B2 | Inhibitors of diacylglycerol acyltransferase | ELI LILLY AND COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110319396-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | MSD K.K. (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2389366-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | MSD K.K. (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-8040502-B2 | Optical inspection of flat media using direct image technology | WDI WISE DEVICE INC. (CA) | 2011-10-18 | — | — | US | disclosed |
| US-20110144091-A1 | Inhibitors of Diacylglycerol Acyltransferase | ELI LILLY AND COMPANY (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144091-A1 | Inhibitors of Diacylglycerol Acyltransferase | ELI LILLY AND COMPANY (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2011071840-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | ELI LILLY AND COMPANY (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010084979-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144091-A1 | Inhibitors of Diacylglycerol Acyltransferase | DGAT1, DGAT2, LCAT | SMN1; SMN2 4170/4885HSD17B10 171/4885CTSL 4528/4885 |
| US-20110319396-A1 | BENZODIAZEPIN-2-ON DERIVATIVES | DGAT1, DGAT2, GRIN1 | SMN1; SMN2 4140/4885HSD17B10 1139/4885CTSL 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.